A comparative analysis of PDX, PDO, and the corresponding tumors using different approaches [45, 47, 51–58, 62, 65, 66], including next-generation sequencing (NGS), has revealed a high fidelity in mutational status between the matched tumor and Patient-derived models, recapitulating most of CRC somatic mutation in several genes including APC, p53, KRAS, NRAS, BRAF, PIK3CA, PTEN [45, 62, 67]. This evidence concerns the gene BRAF and neoplasm.